Abiopharma

🔍 Yellin Jonathan D (Executive)

Company: CRA INTERNATIONAL, INC. (CRAI)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 293 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,588.36 | transaction_form_type: 4 | Footnotes: F1
• Sold 6 shares of Common Stock at $154.55 per share (Direct)
  Date: 2026-04-29 | Code: D | equity_swap_involved: 0 | shares_owned_after: 15,582.00 | transaction_form_type: 4
• Sold 85 shares of Common Stock at $154.55 per share (Direct)
  Date: 2026-04-29 | Code: F | equity_swap_involved: 0 | shares_owned_after: 15,497.00 | transaction_form_type: 4
• Sold 879 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 585.71 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Holds 899 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: H | shares_owned_after: 899.38 | Footnotes: F1, F3, F3
• Holds 1,396 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: H | shares_owned_after: 1,396.00 | Footnotes: F1, F4, F4
• Holds 317 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: H | shares_owned_after: 317.24 | Footnotes: F1, F5, F5
• Holds 557 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: H | shares_owned_after: 556.73 | Footnotes: F1, F6, F6
• Holds 1,090 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: H | shares_owned_after: 1,089.65 | Footnotes: F1, F7, F7
• Holds 2,377 shares of Nonqualified Stock Option (right to buy) at $44.87 per share (Derivative)
  Date: 2026-04-29 | Code: H | Expires: 2027-12-18 | Exercise: 2017-12-18 | shares_owned_after: 2,377.00 | Footnotes: F8
• Holds 2,845 shares of Nonqualified Stock Option (right to buy) at $47.45 per share (Derivative)
  Date: 2026-04-29 | Code: H | Expires: 2028-12-06 | Exercise: 2018-12-06 | shares_owned_after: 2,845.00 | Footnotes: F8

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock; vested RSUs are payable in the form of cash, shares of the Issuer's common stock or a combination thereof, except as otherwise indicated below. To the extent vested RSUs are paid in shares of the Issuer's common stock, such shares will be delivered to the reporting person as soon as possible after vesting, but in no event later than two and one-half months after the end of the year in which vesting occurs, subject to the collection of withholding taxes. Dividend equivalent rights accrue with respect to unvested RSUs in the form of additional RSUs ("Dividend Units") when and as dividends are paid on the Issuer's common stock, and Dividend Units vest on the same dates and in the same relative proportions as the RSUs on which they accrue.
• F2: The RSUs, which include an aggregate of 12.7074 Dividend Units, vest in two equal annual installments beginning on April 29, 2027.
• F3: The RSUs, which include an aggregate of 10.3841 Dividend Units, vest in four equal annual installments beginning on May 20, 2026.
• F4: The RSUs vest in four equal annual installments beginning on April 9, 2027.
• F5: The RSUs, which include an aggregate of 11.2429 Dividend Units, vest on April 11, 2027.
• F6: The RSUs, which include an aggregate of 19.7307 Dividend Units, vest on April 11, 2027.
• F7: The RSUs, which include an aggregate of 23.6478 Dividend Units, vest in two equal annual installments beginning on April 29, 2027.
• F8: Date indicated is date of grant. Option vests in four equal annual installments beginning on the first anniversary of the date of grant.